Redeye provides an update on NextCell following the company’s Q3 report, which came in largely in line with expectations. While 2025 has been a turbulent year so far, the storm is now largely weathered. With a modest valuation and secured funding that covers upcoming potential value inflection points, we reiterate our fair value range.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/